Instem plc Grant of PDMR Options (8614E)
March 15 2022 - 9:49AM
UK Regulatory
TIDMINS
RNS Number : 8614E
Instem plc
15 March 2022
Instem plc
("Instem" or "the Company")
Grant of PDMR Options
Instem plc (AIM: INS), a leading provider of IT solutions to the
global life sciences market, announces that Phil Reason (Chief
Executive Officer) and Nigel Goldsmith (Chief Financial Officer)
have each been granted awards of nil-cost options over 4,833 and
2,165 Ordinary Shares respectively under the Instem plc 2018 Long
Term Incentive Plan ("LTIP"). These options will ordinarily vest
and become exercisable on 1 January 2025 pursuant to the rules of
the LTIP.
After these grants of options, Mr Reason and Mr Goldsmith hold
options over a total of 133,649 and 261,696 Ordinary Shares,
respectively.
For further information, please contact:
Instem plc via Walbrook
Singer Capital Markets (Nominated Adviser
& Broker) +44 (0) 20 7496 3000
Peter Steel
Rachel Hayes
Alex Bond
Stifel Nicolaus Europe Limited (Joint
Broker) +44 (0) 20 7710 7600
Ben Maddison
Alex Price
Walbrook Financial PR +44 (0) 20 7933 8780
Tom Cooper instem@walbrookpr.com
Nick Rome
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Phil Reason
--------------------------------------- ---------------------------------------
2 Reason for the notification
--------------------------------------------------------------------------------
a) Position/status Chief Executive Officer
--------------------------------------- ---------------------------------------
b) Initial notification Initial
/Amendment
--------------------------------------- ---------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor
--------------------------------------------------------------------------------
a) Name Instem plc
--------------------------------------- ---------------------------------------
b) LEI 213800PILYUFNNROQX68
--------------------------------------- ---------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type
of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
--------------------------------------------------------------------------------
a) Description of Grant of nil cost options under
the financial the Company's LTIP
instrument, type
of instrument
Identification GB00B3TQCK30
code
b) Nature of the
transaction Grant of nil cost options under
the Company's LTIP
--------------------------------------- ---------------------------------------
c) Price(s) and
volume(s)
-------------- --------------------
Price Volume(s)
-------------- --------------------
Nil 4,833
----------------------------------------------------------- --------------------
d) Aggregated information
- Aggregated N/A - Single transaction
volume
- Price
e) Date of the transaction 7(th) March 2022
--------------------------------------- ---------------------------------------
f) Place of the Off-market transaction
transaction
--------------------------------------- ---------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Nigel Goldsmith
------------------------------------ --------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------
a) Position/status Chief Financial Officer
------------------------------------ --------------------------------------
b) Initial notification Initial
/Amendment
------------------------------------ --------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor
----------------------------------------------------------------------------
a) Name Instem plc
------------------------------------ --------------------------------------
b) LEI 213800PILYUFNNROQX68
------------------------------------ --------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type
of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
----------------------------------------------------------------------------
a) Description of Ordinary shares of 10p each
the financial
instrument, type
of instrument
Identification GB00B3TQCK30
code
b) Nature of the Grant of nil cost options under
transaction the Company's LTIP
------------------------------------ --------------------------------------
c) Price(s) and
volume(s)
----------------- ----------------
Price(s) Volume(s)
----------------- ----------------
Nil 2,165
----------------------------------------------------------- ----------------
d) Aggregated information N/A - Single Transaction
- Aggregated
volume
- Price
e) Date of the transaction 11(th) March 2022
------------------------------------ --------------------------------------
f) Place of the Off-market transaction
transaction
------------------------------------ --------------------------------------
About Instem
Instem is a leading provider of IT solutions & services to
the life sciences market delivering compelling solutions for Study
Management, Regulatory Submissions, Clinical Trial Acceleration,
and Informatics-based Insight Generation.
Instem solutions are in use by over 700 customers worldwide,
including all of the largest 25 pharmaceutical companies, enabling
clients to bring life enhancing products to market faster. Instem's
portfolio of software solutions increases client productivity by
automating study-related processes while offering the unique
ability to generate new knowledge through the extraction and
harmonisation of actionable scientific information.
Instem products and services address aspects of the entire drug
development value chain, from discovery through to market launch.
Management estimate that over 50% of all drugs on the market have
been through some part of Instem's platform during their
development.
To learn more about Instem solutions and its mission, please visit www.instem.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHUVSORUAUOAAR
(END) Dow Jones Newswires
March 15, 2022 09:49 ET (13:49 GMT)
Instem (LSE:INS)
Historical Stock Chart
From May 2024 to Jun 2024
Instem (LSE:INS)
Historical Stock Chart
From Jun 2023 to Jun 2024
